TrialMatch Studies Benefiting Research on Alzheimer’s & Dementia Disease

We Can All Be Part of the Cure to End Alzheimer’s & Dementia Disease

What is TrialMatch?

Alzheimer’s Association TrialMatch® is a free, easy-to-use clinical studies matching service that generates customized lists of studies based on user-provided information.

Who can participate?

Individuals with dementia or those who are at risk of developing it, caregivers, and healthy volunteers with no dementia issues are urgently needed to participate in more than 250 actively enrolling clinical trials, including both pharmacological (drug) and non-pharmacological (non-drug) studies focused on Alzheimer’s and other dementias.  You can help to accelerate progress and provide valuable insight into potential treatments and methods of prevention.

Don’t Just Hope For a Cure. Help Us Find One.

The Importance of TrialMatch

Without clinical trials, there can be no better treatments, no prevention and no cure for Alzheimer’s disease. Scientists work constantly to find enhanced ways to treat diseases, but improved treatments can never become a reality without testing in clinical trials with human volunteers. Paul Hornback, a Living with Alzheimer’s disease TrialMatch user stated, “When I was first diagnosed I felt like a victim. Participating in a clinical study made me feel like I was taking my life back and doing something to fight this disease.”

According to the Alzheimer’s Latest Facts and Figures:

  • Almost two-thirds of Americans with Alzheimer’s are women.
  • African-Americans are about twice as likely to have Alzheimer’s or other dementias as older whites.
  • Hispanics are about one and one-half times as likely to have Alzheimer’s or other dementias as older whites.

Participating in clinical studies gives us optimism for today and promise for the future. They provide many participants with access to cutting-edge treatments and expert medical care. And some day they will lead us to the end of Alzheimer’s.

Upcoming Findings in Research

The Alzheimer’s Association International Conference® 2017 (AAIC®) is the largest international meeting dedicated to advancing dementia science. Each year, AAIC unites the world’s leading researchers, next generation investigators, clinicians and the care research community to share discoveries in basic and translational research that will lead to methods of prevention and treatment, and improvements in diagnosis for Alzheimer’s disease and other dementias. This year in London, England at ExCeL London, leaders from more than 70 countries to network and discuss the latest dementia study results and theories.

4 Simple Steps to Get Started

Step 1: Access TrialMatch online. For additional assistance email TrialMatch@alz.org or call 800.272.3900 (press 1 for clinical trials).

Step 2: Create your account and answer a few confidential questions to complete a profile. You’ll also have the option to create multiple profiles within your account. For example, one for you, one for a parent and one for a partner or spouse.

Step 3: Submit your answers. TrialMatch will immediately generate your customized list of potential study matches, which you can view on your match results page.

Step 4: Review your match results and decide if you wish to contact any of the studies.

The Alzheimer’s Association TrialMatch® database includes:

  • Treatment trials to test new treatments or combinations of treatments.
  • Diagnostic studies that find new tests or procedures for diagnosing a disease or condition.
  • Prevention trials that investigate ways to prevent the onset of diseases.
  • Quality of life studies that explore ways to improve quality of life for individuals who have a chronic illness, their caregivers and family members.
  • Online studies that are web-based and conducted entirely online.

Want a cure for Alzheimer’s. Get involved today! Visit The Alzheimer’s Research Center for more information.

Isabel Le

Isabel Le is currently the Marketing and Communications intern at The Alzheimer's Association Houston and Southeast Chapter. She will graduate Texas A&M University in May of 2018 with a major in Communication and minor in Business.